Protagonist Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.06.24	These Biotech Stocks Hit New Highs, Did You Reap The Rewards? (RTTNews)
11.05.23	Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association (PR Newswire)
05.04.23	Protagonist Therapeutics Declines 8% After Pricing 5 Mln Share Offering (RTTNews)
07.03.23	Protagonist's Phase 2b Trial Of JNJ-2113 In Psoriasis Achieved Primary Efficacy Endpoint (RTTNews)
07.03.23	Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis (PR Newswire)
02.11.22	Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer (PR Newswire)
20.09.22	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire)
04.05.22	Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
25.04.22	Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis (PR Newswire)
25.04.22	TOP RANKED ROSEN LAW FIRM Encourages Protagonist Therapeutics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - PTGX (PR Newswire)
16.03.22	Protagonist Gets $25 Mln Milestone Payment From Janssen (RTTNews)
17.09.21	FDA Places Clinical Hold On Protagonist's Clinical Studies For Rusfertide - Quick Facts (RTTNews)
10.08.21	Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma (PR Newswire)
04.08.21	Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress (PR Newswire)
28.07.21	Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists (PR Newswire)
30.06.21	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire)
11.06.21	Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera (PR Newswire)
08.10.20	Pre-market Movers In Healthcare Sector: CDNA, IMTX, REGN, CRSP, TLC... (RTTNews)
18.06.20	Stock Alert: Protagonist Therapeutics Up 10% As Hepcidin Mimetic PTG-300 Gets Orphan Drug Status (RTTNews)
05.12.19	Today's Top Gainers: PTGX Bounces Back, ALLK Abuzz, AVXL On The Move... (RTTNews)
04.12.19	Healthcare Stocks That Plunged To New Lows (PTGX, TRPX, MTP...) (RTTNews)
04.12.19	ARDX Jumps On PHREEDOM Data, AXSM Is Awesome, CARA On Watch (RTTNews)
11.09.19	5 Top Losers In Healthcare Sector (EMMA, MBOT, XERS…) (RTTNews)
15.08.18	OptiNose Dives To New Low, ReWalk Tumbles, SYN Down 60% This Month (RTTNews)
07.08.18	Recheck Propels PTGX, Analysts Boost Price Target On ICPT, Watch Out For AMPE (RTTNews)
18.06.18	Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting (PR Newswire)
06.06.18	Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference (PR Newswire)
01.06.18	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire)
24.05.18	Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer (PR Newswire)
17.05.18	Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association (PR Newswire)
16.05.18	Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors (PR Newswire)
09.05.18	Protagonist Therapeutics Reports First Quarter 2018 Financial Results (PR Newswire)
08.05.18	Sangamo Therapeutics Reports First Quarter 2018 Financial Results (PR Newswire)
03.05.18	Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference (PR Newswire)
27.03.18	DXR Continues To Slide, Keep An Eye On ASNS, Data Fails To Propel PTGX (RTTNews)
26.03.18	Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial Of PTG-100 (RTTNews)
26.03.18	Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis (PR Newswire)
18.03.18	An Ear To The Pharma: 11 Stocks To Watch This Week (RTTNews)
09.03.18	Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference (PR Newswire)
06.03.18	FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia (PR Newswire)
01.03.18	Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference (PR Newswire)
01.03.18	Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow (PR Newswire)
07.02.18	KALA Down 33% YTD, HAIR Recedes, Mark Your Calendar For Feb.23 (RTTNews)
31.01.18	Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference (PR Newswire)
30.01.18	AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX Soars (RTTNews)
04.01.18	Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 (PR Newswire)
14.12.17	Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors (PR Newswire)
14.12.17	Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 (PR Newswire)
04.12.17	Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference (PR Newswire)
09.11.17	Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	77.04	2.86 %	K V
CieFinRichemont	138.05	2.83 %	K V
UBS Group	28.99	1.86 %	K V
Sika	215.90	1.41 %	K V
Lonza Grp	537.00	0.56 %	K V
Swiss Life Hldg	708.80	-0.53 %	K V
Alcon	75.92	-0.60 %	K V
Sonova Hldg	292.00	-1.48 %	K V
Nestle	73.36	-1.79 %	K V
Givaudan	3’849.00	-2.43 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Protagonist Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten